Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 3INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 4Thoracic 3Other hematologic neoplasm 3Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × obatoclax × Other hematologic neoplasm × Clear all
NCT00438178 2014-05-12

Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
44 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT00600964 2014-05-12

A Phase I/II Study of GX15-070MS in Untreated CLL

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1 Completed
26 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00684918 2013-08-26

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
18 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡